Juno Lighting Inc | TalkMarkets

Latest Posts

4 Biotech Stocks That More Than Doubled This Year

Article By: Zacks Investment Research

Saturday, December 23, 2017 7:50 PM EDT

The biotech industry has been on the comeback trail in 2017 after facing challenges including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for key drugs.

In this article: JUNO, BLUE, XOMA, PBYI, PIRS, ALNY Also: CELG

Read

3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Article By: Arpita Dutt

Monday, December 11, 2017 7:45 PM EDT

At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.

In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD

Read

Ford Model T And Personalized Medicine

Article By: Ketan Desai

Monday, December 11, 2017 10:35 AM EDT

While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?

In this article: JUNO, KITE, EDIT

Read

XBI Breaks Through On A Strong Week For Biotech

Article By: Rod Raynovich

Friday, September 29, 2017 7:25 PM EDT

The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.

In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI

Read

Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma

Article By: The Fly

Monday, August 28, 2017 8:05 PM EDT

Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.

In this article: GILD, JUNO, KITE, BLUE, CLLS

Read

All Posts